FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008551470> ?p ?o ?g. }

• W2008551470 endingPage "95" @default.
• W2008551470 startingPage "95" @default.
• W2008551470 abstract "The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life Roy FleischmannMetroplex Clinical Research Center, Dallas, Texas, USAAbstract: Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentioned by patients as their most debilitating problem. In the era prior to biologic therapy in rheumatoid arthritis, it was reported that 40% to 50% of individuals reported work loss within 10 years of the onset of their disease. Rheumatoid arthritis is not just associated with chronic pain and inability to function normally; there is a significant economic burden caused by the disease which affects society as well the individual. Work disability in individuals with rheumatoid arthritis occurs early and increases over time. Early, aggressive treatment has now become the norm in clinical practice with changes of medication dictated by measuring the presence of continued disease activity. The combination of adequately dosed methotrexate and a biologic agent, especially a TNFα inhibitor, has been shown to be far more effective than traditional disease modifying anti-rheumatic drugs in early and long-standing disease, with respect to clinical, radiologic and functional outcomes. Unfortunately, not all patients respond to all medications equally; indeed a patient may fail a number of medications, either alone or in combination, and then respond to another medication. For this reason, there is room in our therapeutic armamentarium for additional effective agents such as certolizumab pegol. The results of up to 100 weeks of treatment with certolizumab pegol with an emphasis on functional outcomes, is the focus of this review.Keywords: certolizumab, rheumatoid arthritis, anti-TNF therapy; efficacy, safety, quality of life" @default.
• W2008551470 created "2016-06-24" @default.
• W2008551470 creator A5046261111 @default.
• W2008551470 date "2009-07-01" @default.
• W2008551470 modified "2023-10-16" @default.
• W2008551470 title "The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life" @default.
• W2008551470 cites W1492940207 @default.
• W2008551470 cites W1578375703 @default.
• W2008551470 cites W1601868150 @default.
• W2008551470 cites W1855237237 @default.
• W2008551470 cites W1884756792 @default.
• W2008551470 cites W1908888716 @default.
• W2008551470 cites W1984009427 @default.
• W2008551470 cites W1987453516 @default.
• W2008551470 cites W1993967170 @default.
• W2008551470 cites W1996389186 @default.
• W2008551470 cites W1999777294 @default.
• W2008551470 cites W2006566716 @default.
• W2008551470 cites W2011487877 @default.
• W2008551470 cites W2014709373 @default.
• W2008551470 cites W2016716920 @default.
• W2008551470 cites W2019114331 @default.
• W2008551470 cites W2024644107 @default.
• W2008551470 cites W2028971378 @default.
• W2008551470 cites W2033299724 @default.
• W2008551470 cites W2054765588 @default.
• W2008551470 cites W2056179428 @default.
• W2008551470 cites W2059984620 @default.
• W2008551470 cites W2065344034 @default.
• W2008551470 cites W2066409058 @default.
• W2008551470 cites W2069456468 @default.
• W2008551470 cites W2072677308 @default.
• W2008551470 cites W2091732273 @default.
• W2008551470 cites W2092195959 @default.
• W2008551470 cites W2098293486 @default.
• W2008551470 cites W2099199787 @default.
• W2008551470 cites W2099885994 @default.
• W2008551470 cites W2107883387 @default.
• W2008551470 cites W2111153776 @default.
• W2008551470 cites W2113609304 @default.
• W2008551470 cites W2114308202 @default.
• W2008551470 cites W2116843833 @default.
• W2008551470 cites W2122265491 @default.
• W2008551470 cites W2124670599 @default.
• W2008551470 cites W2130498680 @default.
• W2008551470 cites W2134171514 @default.
• W2008551470 cites W2137110634 @default.
• W2008551470 cites W2148964193 @default.
• W2008551470 cites W2151739985 @default.
• W2008551470 cites W2152348310 @default.
• W2008551470 cites W2153255333 @default.
• W2008551470 cites W2154515402 @default.
• W2008551470 cites W2156665585 @default.
• W2008551470 cites W2156996668 @default.
• W2008551470 cites W2160868103 @default.
• W2008551470 cites W2161344815 @default.
• W2008551470 cites W2162716725 @default.
• W2008551470 cites W2163817180 @default.
• W2008551470 cites W2298627702 @default.
• W2008551470 cites W2302652017 @default.
• W2008551470 cites W2340084730 @default.
• W2008551470 cites W2413265834 @default.
• W2008551470 cites W2417787877 @default.
• W2008551470 cites W48703373 @default.
• W2008551470 cites W53352406 @default.
• W2008551470 doi "https://doi.org/10.2147/oarrr.s4904" @default.
• W2008551470 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5074715" @default.
• W2008551470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27789984" @default.
• W2008551470 hasPublicationYear "2009" @default.
• W2008551470 type Work @default.
• W2008551470 sameAs 2008551470 @default.
• W2008551470 citedByCount "3" @default.
• W2008551470 countsByYear W20085514702012 @default.
• W2008551470 countsByYear W20085514702016 @default.
• W2008551470 countsByYear W20085514702022 @default.
• W2008551470 crossrefType "journal-article" @default.
• W2008551470 hasAuthorship W2008551470A5046261111 @default.
• W2008551470 hasBestOaLocation W20085514701 @default.
• W2008551470 hasConcept C126322002 @default.
• W2008551470 hasConcept C159110408 @default.
• W2008551470 hasConcept C177713679 @default.
• W2008551470 hasConcept C1862650 @default.
• W2008551470 hasConcept C2776215756 @default.
• W2008551470 hasConcept C2777077863 @default.
• W2008551470 hasConcept C2777575956 @default.
• W2008551470 hasConcept C2779134260 @default.
• W2008551470 hasConcept C2779951463 @default.
• W2008551470 hasConcept C2780132546 @default.
• W2008551470 hasConcept C535046627 @default.
• W2008551470 hasConcept C71924100 @default.
• W2008551470 hasConceptScore W2008551470C126322002 @default.
• W2008551470 hasConceptScore W2008551470C159110408 @default.
• W2008551470 hasConceptScore W2008551470C177713679 @default.
• W2008551470 hasConceptScore W2008551470C1862650 @default.
• W2008551470 hasConceptScore W2008551470C2776215756 @default.
• W2008551470 hasConceptScore W2008551470C2777077863 @default.
• W2008551470 hasConceptScore W2008551470C2777575956 @default.
• W2008551470 hasConceptScore W2008551470C2779134260 @default.

• next